



Patent Application
Attorney Docket No. PC24974A

I hereby certify that this correspondence is being deposited as first class mail with sufficient postage and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 17th day of October 2005.

By

(Signature of person mailing)

A. David Joran

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Erik Ho Fong Wong :

APPLICATION NO. : 10/602,447

: Examiner:

FILING DATE: June 24, 2003

: Group Art Unit: 1614

TITLE: METHOD OF PROMOTING SMOKING :
CESSATION :

Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.


Respectfully submitted,

A handwritten signature in black ink, appearing to read 'A. David Joran', written over a horizontal line.

A. David Joran
Registration No. 37,858
Attorney for Applicants

Date: October 17, 2004

Pfizer, Inc.
Patent Department
150 East 42nd Street
New York, NY 10017
(212) 733-3381



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. 24974A					SERIAL NO. 10/602,447									
										APPLICANT Erik Fo Hong Wong														
										FILING DATE June 24, 2003					GROUP 1614									
U.S. PATENT DOCUMENTS																								
EXAMINER INITIAL	DOCUMENT NUMBER									DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE										
	0	2	0	0	1	3	3	1	2	31-Jan-02	J. Schildkraut													
FOREIGN PATENT DOCUMENTS																								
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION											
													YES	NO										
	0	0	0	5	9	4	8	6	12-Oct-00	WO														
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																								
			Harkin A. <i>et al.</i> , "Activity and onset of action of reboxetine and effects of combination of sertraline in an animal model of depression", <i>Europ. J. of Pharmacology</i> , Vol. 365, 1999, pps. 123-132																					
			Harkin A. <i>et al.</i> , "Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and β 1-adrenergic receptors in an animal model of depression", <i>J. Neural Transmission</i> , Vol 107, 2000, pps. 1213-1227																					
			Ferri M. <i>et al.</i> , "Sertraline and reboxetine association in depressive pseudodementia: good cardiovascular effects", <i>Arch. Gerontol. Geriatrics, Suppl. 7</i> 2001 pps 121-125																					
			Demitrack, M.A., "Can Monoamine-Based Therapies Be Improved?", <i>J. Clinical Psychiatry</i> Vol. 63, 2002																					
EXAMINER										DATE CONSIDERED														
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																								